Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Ocaliva

    - PMLiVE

    GSK shares promising phase 3 results for linerixibat in PBC-related itch

    Pruritus is experienced by up to 90% of patients with the rare liver disease

    - PMLiVE

    Gilead’s seladelpar granted conditional EC approval to treat rare liver disease PBC

    Primary biliary cholangitis affects approximately 163,000 people in Europe

    - PMLiVE

    Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults

    The company gained access to the drug through its $4.3bn acquisition of CymaBay

    - PMLiVE

    Gilead’s seladelpar recommended by CHMP to treat primary biliary cholangitis

    The rare liver disease affects approximately 15 per 100,000 people in Europe

    - PMLiVE

    GSK’s linerixibat shows promise in phase 3 primary biliary cholangitis trial

    An estimated 510,000 people will be diagnosed with the rare liver disease globally by 2030

    - PMLiVE

    Ipsen shares positive three-year results for Iqirvo in primary biliary cholangitis

    The rare liver disease affects approximately 100,000 people in the US

    - PMLiVE

    Ipsen’s Iqirvo recommended by NICE to treat rare liver disease primary biliary cholangitis

    The disease affects approximately 25,000 people in the UK, the majority of whom are women

    - PMLiVE

    Ipsen’s Iqirvo approved by MHRA to treat primary biliary cholangitis in adults

    Approximately 25,000 people in the UK are affected by the rare liver disease

    - PMLiVE

    Ipsen’s Iqirvo receives EC approval to treat primary biliary cholangitis in adults

    The rare liver disease affects approximately nine women for every one man

    - PMLiVE

    Gilead’s Livdelzi receives FDA accelerated approval to treat primary biliary cholangitis

    The company gained access to the drug through its $4.3bn acquisition of CymaBay in March

    - PMLiVE

    Calliditas announces promising results for NOX enzyme inhibitor in rare liver disease

    Primary biliary cholangitis is estimated to affect approximately 140,000 patients in the US

    - PMLiVE

    Ipsen’s Iqirvo receives FDA approval to treat adults with primary biliary cholangitis

    The rare cholestatic liver disease currently affects approximately 100,000 people in the US

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links